Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO was a Mainboard book-built issue of ₹1,757 crore, comprising a Fresh Issue of ₹150 crore and an Offer for Sale of ₹1,607 crore. The price band was ₹938 to ₹988 per share, with a lot size of 15 shares.
Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab IPO opened for public subscription on August 24, 2026 and closed on August 27, 2026. The basis of allotment was finalized on August 28, refunds were scheduled to begin on August 31, shares were scheduled to be credited to Demat accounts on August 31, and the shares were scheduled to be listed on BSE and NSE on September 1, 2026.
Symbiotec Pharmalab IPO GMP
The latest reported Symbiotec Pharmalab IPO GMP on August 27, 2026 was approximately ₹282 against the ₹988 upper price band, indicating an unofficial estimated price of around ₹1,270. GMP is unofficial grey-market information and does not guarantee the actual listing price.
Symbiotec Pharmalab IPO Timeline (Tentative)
Symbiotec Pharmalab IPO opened on August 24, 2026 and closed on August 27, 2026. The basis of allotment was finalized on August 28, followed by refund initiation and Demat credit scheduled for August 31. The shares were scheduled to list on BSE and NSE on September 1, 2026.
| Event | Tentative Date |
|---|---|
| IPO Open Date | Mon, Aug 24, 2026 |
| IPO Close Date | Thu, Aug 27, 2026 |
| Basis of Allotment | Fri, Aug 28, 2026 |
| Initiation of Refunds | Mon, Aug 31, 2026 |
| Credit of Shares to Demat | Mon, Aug 31, 2026 |
| Listing Date | Tue, Sep 1, 2026 |
| IPO Opens | August 24, 2026 |
| IPO Closes | August 27, 2026 |
| Basis of Allotment | August 28, 2026 |
| Refund Initiation | August 31, 2026 |
| Credit of Shares to Demat | August 31, 2026 |
| Listing Date | September 1, 2026 |
Symbiotec Pharmalab IPO Lot Size
The Symbiotec Pharmalab IPO lot size was 15 shares. At the upper price band of ₹988 per share, one lot required an investment of ₹14,820. Retail investors could apply for up to 13 lots, or 195 shares, amounting to ₹1,92,660.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 15 | 14,820 |
| Retail (Max) | 13 | 195 | 1,92,660 |
| S-HNI (Min) | 14 | 210 | 2,07,480 |
| S-HNI (Max) | 67 | 1,005 | 9,92,940 |
| B-HNI (Min) | 68 | 1,020 | 10,07,760 |
Symbiotec Pharmalab IPO Reservation
The Symbiotec Pharmalab IPO allocation included the prescribed categories for Qualified Institutional Buyers, Non-Institutional Investors and Retail Individual Investors. The offer also included an employee reservation portion and an anchor investor allocation within the QIB portion.
Symbiotec Pharmalab IPO Subscription
Symbiotec Pharmalab IPO received 71.26x overall subscription by the close of bidding on August 27, 2026. The QIB portion was subscribed 172.03x, the NII portion 73.63x and the Retail Individual Investor portion 12.96x.
| Category | Subscription (times) |
|---|---|
| QIB | 172.03x |
| NII | 73.63x |
| RII | 12.96x |
| Total | 71.26x |
About Symbiotec Pharmalab
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. The company operates as a contract development and manufacturing organisation for specialty pharmaceutical and nutraceutical companies while also manufacturing its own products.
The company has a strong focus on Active Pharmaceutical Ingredients, particularly corticosteroid and steroidal hormone APIs. Its portfolio also includes fermentation-based APIs, nutritional ingredients and specialty products. The company combines research, manufacturing and regulatory capabilities across its operating platforms.
Symbiotec operates manufacturing facilities and research capabilities in Madhya Pradesh. Its official website identifies facilities at Rau and Pithampur, while the RHP also discloses additional subsidiary facilities and an expanded fermentation capacity.
The company serves customers in India and overseas markets. Revenue from external customers outside India represented 67.04% of revenue from operations in Fiscal 2026, showing the importance of international markets to its business.
Strengths
- Research-driven pharmaceutical and biotechnology business model.
- Capabilities across organic chemistry, biotechnology and complex injectables.
- Strong focus on corticosteroid and steroidal hormone APIs.
- Integrated manufacturing and research capabilities.
- International customer and export presence.
- Growing fermentation capacity and API development capabilities.
- Established experience in pharmaceutical manufacturing and regulatory compliance.
Risks to Consider
- A substantial portion of revenue comes from APIs, with the top five APIs accounting for 67.27% of revenue from operations in Fiscal 2026.
- Manufacturing facilities are subject to inspections and audits by regulatory authorities and customers.
- A significant portion of revenue comes from international markets, exposing the company to export-related risks.
- Revenue from the United States represented 13.12% of revenue from operations in Fiscal 2026.
- The company depends on certain key customers, with its top ten customers contributing 57.59% of product-sale revenue in Fiscal 2026.
- Manufacturing facilities and dedicated R&D centres are concentrated in Madhya Pradesh.
- The company depends on certain suppliers for raw materials.
- The pharmaceutical and CDMO markets are highly competitive.
- Some raw materials are sourced internationally, including from China and the United States.
- The success of the business depends partly on successful research, development and commercialization of new products.
Symbiotec Pharmalab Financials (₹ Cr)
Symbiotec Pharmalab recorded growth in revenue from operations and EBITDA between FY2024 and FY2026. Revenue from operations increased from ₹716.25 crore in FY2024 to ₹869.15 crore in FY2026, while PAT increased from ₹100.06 crore to ₹109.90 crore. Net worth increased to ₹1,158.64 crore in FY2026.
| Period | Revenue | PAT | Total Assets | Net Worth |
|---|---|---|---|---|
| FY2024 | 716.25 | 100.06 | 1,294.79 | 720.68 |
| FY2025 | 751.55 | 96.79 | 1,579.65 | 821.15 |
| FY2026 | 869.15 | 109.90 | 1,780.79 | 1,158.64 |
KPIs & Valuation
At the upper IPO price band of ₹988, Symbiotec Pharmalab had a pre-IPO EPS of ₹17.82 and a post-IPO EPS of ₹17.39. The corresponding P/E ratios were approximately 55.44x and 56.81x. FY2026 RoNW was 9.48%, NAV was ₹184.69 per share and ROCE was 11.56%.
Objects of the Issue
The Fresh Issue proceeds are proposed to be used mainly for prepayment or repayment of certain outstanding borrowings of the company. The balance of the Net Proceeds is proposed to be used for general corporate purposes. The company has proposed an estimated ₹112.50 crore for repayment or prepayment of borrowings.
- The company proposed to utilise the IPO proceeds for:
- Prepayment and/or repayment, in full or in part, of certain outstanding borrowings availed by the company – ₹112.50 crore.
- General corporate purposes.
- The company will not receive any proceeds from the Offer for Sale portion; those proceeds will accrue to the respective selling shareholders after applicable deductions.
Promoters, Lead Managers & Registrar
Symbiotec Pharmalab Limited is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited acted as the Book Running Lead Managers. MUFG Intime India Private Limited acted as the Registrar to the Offer.
Promoters
Lead Managers (BRLM)
Registrar
| Name | MUFG Intime India Private Limited |
|---|---|
| Phone | +91 810 811 4949 |
| symbiotecpharmalab.ipo@in.mpms.mufg.com | |
| Website | https://in.mpms.mufg.com/Initial_Offer/public-issues.html |
Symbiotec Pharmalab IPO Review
Symbiotec Pharmalab reported revenue from operations of ₹716.25 crore in FY2024, ₹751.55 crore in FY2025 and ₹869.15 crore in FY2026. Profit after tax stood at ₹100.06 crore, ₹96.79 crore and ₹109.90 crore respectively during these years.
The company has maintained a strong EBITDA margin, which stood at 26.59% in FY2026 compared with 27.26% in FY2025 and 24.48% in FY2024. PAT margin was 12.60% in FY2026.
Net worth increased from ₹720.68 crore in FY2024 to ₹821.15 crore in FY2025 and ₹1,158.64 crore in FY2026. Total assets increased to ₹1,780.79 crore in FY2026 from ₹1,294.79 crore in FY2024.
At the upper IPO price of ₹988, the reported pre-IPO EPS was ₹17.82 and post-IPO EPS was ₹17.39. This resulted in a pre-issue P/E of approximately 55.44x and a post-issue P/E of approximately 56.81x.
How to Apply
Symbiotec Pharmalab IPO applications could be made through the ASBA process, including UPI-supported applications. The minimum application consisted of one lot of 15 shares, requiring ₹14,820 at the upper price band of ₹988.
Through UPI
- Log in to your stockbroker app or website.
- Go to the IPO section.
- Select Symbiotec Pharmalab IPO.
- Enter the number of lots you want to apply for.
- Select the applicable bid price or Cut-off option where permitted.
- Enter your valid UPI ID.
- Submit the IPO application.
- Open your UPI app when the mandate request arrives.
- Approve the mandate using your UPI PIN.
- The application amount will be blocked in your bank account. If shares are allotted, the required amount will be debited; otherwise, the blocked amount will be released.
Prospectus & Documents
Investors can refer to the company's Red Herring Prospectus and other offer documents for detailed information relating to its business, financial performance, risk factors, objects of the issue, capital structure and other statutory disclosures. The RHP dated August 18, 2026 was filed with the Registrar of Companies, Madhya Pradesh at Gwalior and is available through SEBI and the company's investor website.
Last updated Aug 29, 2026.